JP2007248395A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007248395A5 JP2007248395A5 JP2006075498A JP2006075498A JP2007248395A5 JP 2007248395 A5 JP2007248395 A5 JP 2007248395A5 JP 2006075498 A JP2006075498 A JP 2006075498A JP 2006075498 A JP2006075498 A JP 2006075498A JP 2007248395 A5 JP2007248395 A5 JP 2007248395A5
- Authority
- JP
- Japan
- Prior art keywords
- acute coronary
- coronary syndrome
- adamts13
- amount
- von willebrand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 36
- 108010047303 von Willebrand Factor Proteins 0.000 claims 34
- 102100036537 von Willebrand factor Human genes 0.000 claims 30
- 229960001134 von willebrand factor Drugs 0.000 claims 30
- 102100032290 A disintegrin and metalloproteinase with thrombospondin motifs 13 Human genes 0.000 claims 17
- 108091005670 ADAMTS13 Proteins 0.000 claims 17
- 238000000034 method Methods 0.000 claims 15
- 201000010099 disease Diseases 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 14
- 230000000694 effects Effects 0.000 claims 12
- 102000004190 Enzymes Human genes 0.000 claims 10
- 108090000790 Enzymes Proteins 0.000 claims 10
- 230000000593 degrading effect Effects 0.000 claims 7
- 238000001514 detection method Methods 0.000 claims 7
- 239000003153 chemical reaction reagent Substances 0.000 claims 6
- 238000012544 monitoring process Methods 0.000 claims 4
- 230000001502 supplementing effect Effects 0.000 claims 4
- 235000009421 Myristica fragrans Nutrition 0.000 claims 3
- 239000001115 mace Substances 0.000 claims 3
- 238000003745 diagnosis Methods 0.000 claims 2
- 238000004393 prognosis Methods 0.000 claims 2
- 230000009469 supplementation Effects 0.000 claims 2
- 238000011156 evaluation Methods 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006075498A JP4820192B2 (ja) | 2006-03-17 | 2006-03-17 | 急性冠症候群でのａｄａｍｔｓ１３の測定と利用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006075498A JP4820192B2 (ja) | 2006-03-17 | 2006-03-17 | 急性冠症候群でのａｄａｍｔｓ１３の測定と利用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007248395A JP2007248395A (ja) | 2007-09-27 |
| JP2007248395A5 true JP2007248395A5 (enExample) | 2009-04-23 |
| JP4820192B2 JP4820192B2 (ja) | 2011-11-24 |
Family
ID=38592839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006075498A Expired - Lifetime JP4820192B2 (ja) | 2006-03-17 | 2006-03-17 | 急性冠症候群でのａｄａｍｔｓ１３の測定と利用 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4820192B2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3072978T (pt) | 2002-05-09 | 2018-10-15 | Brigham & Womens Hospital Inc | 1l1rl-1 como um marcador de doença cardiovascular |
| ES2529618T3 (es) | 2006-04-24 | 2015-02-23 | Critical Care Diagnostics, Inc. | Predicción de la mortalidad y detección de enfermedades graves |
| ES2566169T3 (es) | 2006-05-01 | 2016-04-11 | Critical Care Diagnostics, Inc. | Diagnóstico de enfermedad cardiovascular |
| JP5254973B2 (ja) | 2007-06-22 | 2013-08-07 | 一般財団法人化学及血清療法研究所 | 新規ａｄａｍｔｓ−１３改変体 |
| DK2660599T3 (en) * | 2008-04-18 | 2014-12-08 | Critical Care Diagnostics Inc | PREDICTION OF RISK OF MAJOR ADVERSE HEART EVENTS |
| CA2745805C (en) * | 2008-12-05 | 2021-01-19 | Baxter International Inc. | Methods of measuring adamts13-mediated in vivo cleavage of von willebrand factor and uses thereof |
| JP5715137B2 (ja) * | 2009-08-31 | 2015-05-07 | アボット・ラボラトリーズＡｂｂｏｔｔ Ｌａｂｏｒａｔｏｒｉｅｓ | 主要有害心イベントの予測のためのバイオマーカーおよびその使用 |
| HK1212057A1 (en) | 2012-08-21 | 2016-06-03 | 重症监护诊断股份有限公司 | Multimarker risk stratification |
| CN103808944B (zh) * | 2014-03-07 | 2016-04-20 | 高平 | 生物标志物vwf和adamts13及其在肝硬化诊断试剂中的用途 |
| AU2017343623A1 (en) | 2016-10-11 | 2019-04-18 | Laboratory Corporation Of America Holdings | Methods and systems for determining adamts13 enzyme activity |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002529373A (ja) * | 1998-10-23 | 2002-09-10 | ザ ブリガム アンド ウィメンズ ホスピタル，インコーポレイテッド | コンホメーション特異的抗ｖｏｎＷｉｌｌｅｂｒａｎｄ因子抗体 |
| JP4666942B2 (ja) * | 2003-04-25 | 2011-04-06 | 学校法人慶應義塾 | フォンビルブラント因子切断酵素遺伝子解析による血栓性疾患関連の遺伝子変異検出方法 |
| US7780831B2 (en) * | 2003-07-07 | 2010-08-24 | The University Of North Carolina At Chapel Hill | Assays for detection of von willebrand factor (vWF) multimers and for degradation of vWF by agents such as ADAMTS13 and related methods |
| JP4398188B2 (ja) * | 2003-07-09 | 2010-01-13 | 積水メディカル株式会社 | 急性冠症候群およびその病態の検査方法 |
| CN1898567A (zh) * | 2003-12-22 | 2007-01-17 | 株式会社三菱化学药得论 | 通过测定冯维勒布兰德因子分解酶检测血栓症的方法 |
-
2006
- 2006-03-17 JP JP2006075498A patent/JP4820192B2/ja not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009501333A5 (enExample) | ||
| Saenger et al. | Multicenter analytical evaluation of a high-sensitivity troponin T assay | |
| Póvoa et al. | Early identification of intensive care unit-acquired infections with daily monitoring of C-reactive protein: a prospective observational study | |
| Martinelli et al. | High levels of factor VIII and risk of extra-hepatic portal vein obstruction | |
| Francisco et al. | Serum markers of vascular inflammation in dyslipemia | |
| Pieri et al. | Serum Amyloid A Protein as a useful biomarker to predict COVID-19 patients severity and prognosis | |
| PL2386860T3 (pl) | Przewidywanie śmiertelności i wykrywanie poważnej choroby | |
| JP2011526693A5 (enExample) | ||
| JP2005509161A5 (enExample) | ||
| JP2008533471A5 (enExample) | ||
| DE602004030586D1 (de) | Verfahren zur verwendung von cytokintests zur diagnose, behandlung und beurteilung von ankyloider spondylitis | |
| JP2018529931A5 (enExample) | ||
| Pierce et al. | C-reactive protein, interleukin-6, and prostate cancer risk in men aged 65 years and older | |
| JP2008537474A5 (enExample) | ||
| HRP20130127T1 (hr) | Prediktivni biomarkeri bubrežne sigurnosti i potpisi biomarkera za praä†enje funkcije bubrega | |
| JP2023503379A5 (enExample) | ||
| CA2667957A1 (en) | Methods and apparatuses for electrochemical determination of factor xa inhibitors in blood samples | |
| JP2004530114A5 (enExample) | ||
| JP2020514689A5 (enExample) | ||
| RU2016137685A (ru) | Способ диагностики туберкулеза | |
| JP2007033132A5 (enExample) | ||
| EP1200837A1 (en) | A method for predicting the presence of haemostatic dysfunction in a patient sample | |
| Wassell et al. | Faecal calprotectin: a new marker for Crohn's disease? | |
| Mentesoglu et al. | The association between Behçet disease activity and elevated systemic immune-inflammation index: A retrospective observational study in a tertiary care hospital. | |
| Madhurantakam et al. | COVID severity test (CoST sensor)—An electrochemical immunosensing approach to stratify disease severity |